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Influenza treatment with antioxidants
Application of various antioxidants
in the treatment of influenza
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Abstract
We determined the effect of the antioxidants superoxide dismutase,
desferrioxamine and allopurinol on the survival of male CBA mice
infected intranasally with 2-5 LD50 lung influenza virus A/Aichi/2/68.
Survival for at least 20 days was observed for 45% of the mice that
received 1000 U/day superoxide dismutase prepared from red blood
cells on days 5, 6, 7 and 8 after infection, and 75% survival was
observed for mice that received the same dose on days 4, 5, 6, 7 and 8.
Desferrioxamine, 25 mg/kg per day and 100 mg/kg per day injected
subcutaneously, resulted in survival rates of 5 and 0%, respectively,
compared to 10% survival observed for saline-injected controls. Al-
lopurinol at doses of 5 to 50 mg/kg per day had no effect on mouse
survival. These data demonstrate the efficacy of superoxide dismutase
for the protection of mice against hemorrhagic lung edema. The
ineffectiveness of allopurinol suggests that the xanthine oxidase sys-
tem does not play a major role in hemorrhage or lung edema and that
caution is necessary when desferrioxamine is administered during an
acute inflammatory process accompanied by erythrocyte lysis.
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The question of how to effectively treat
influenza infection after the onset of virus
resistance to typical chemotherapeutic drugs
is still unsolved (1). The effectiveness of
most anti-influenza drugs correlates with the
suppression of virus reproduction and this is
why these medications are effective only
during the early phase of infection when
intensive reproduction of the virus takes place
in the upper respiratory tract epithelium and
are ineffective later during infection when
virus multiplication no longer plays a major
role in the development of the infection. The
role of free radical processes in the patho-
genesis of influenza-induced hemorrhagic
lung edema has been reported and the poten-
tial treatment with antioxidant drugs has been
discussed recently (2,3).
The objective of the present study was to
compare the action of some antioxidants on
mouse survival during influenza infection.
It has been proposed that superoxide radi-
cal (O2
· · · · ·-) generation plays an important role
in the pathogenesis of influenza infection
and it is assumed that the xanthine-xanthine
oxidase system is responsible for O2
· · · · ·- gen-
eration and for the activation of free radical
processes during influenza (4). Since allopu-
rinol is a powerful inhibitor of xanthine oxi-
dase (5) we used this drug in our experi-
ments.
We also studied superoxide dismutase
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(SOD), an enzyme that catalyzes the inacti-
vation of the superoxide radical by a dismu-
tation reaction (5):
O2
· · · · ·- + O2
· · · · ·- + 2 H+ ® H2O2 + O2
Thus, SOD was used in our experiments
to trap O2
· · · · ·- which is generally considered to
be the major factor in oxygen toxicity (5).
The morphological substrate of influenza
infection is hemorrhagic lung edema and
influenza virus can induce erythrocyte
hemolysis with the release of hemoglobin
(6). The iron released from hemoglobin can
catalyze the Haber-Weiss reaction forming
hydroxyl radicals (7):
H2O2 + O2
· · · · ·- ® O2 + OH· · · · · + OH-
Fe
The reactivity of hydroxyl radicals is so
great that, when formed in a living system,
they will react immediately with whatever
biological molecule is in their vicinity, thus
producing secondary radical(s). Since the
iron chelator desferrioxamine (DEF) is a
powerful inhibitor of hydroxyl radical for-
mation dependent on the presence of iron
salts (8), DEF was used as the third drug in
our experiments.
Male mice of the CBA line were infected
intranasally with lung influenza virus A/
Aichi/2/68 (H2N2) adapted to mice at the
dose of 2-5 LD50. Desferrioxamine B (Des-
feral) was obtained from Ciba-Geigy (Basel,
Switzerland) and administered subcutane-
ously at a daily dose of 5 to 150 mg/kg, twice
a day. Human erythrocyte superoxide dis-
mutase was obtained from AO Rosbio (St.
Petersburg, Russia) and administered iv at
the dose of 1000 U once a day. Allopurinol
was purchased from Sigma (St. Louis, MO)
and administered orally at doses of 5 to 50
mg/kg once a day.
All drugs were administered during the
late period of infection on the 4th or 5th day
after virus inoculation. The control group of
infected mice received saline  iv or heat-
inactivated SOD.
Mouse survival curves for different treat-
ments are shown in Figure 1. Mice that re-
ceived saline or heat-inactivated SOD (curve
1) had similar 10% survival rates. SOD was
effective (45% survival) in protecting the
mice when given on days 5, 6, 7 and 8 (curve
2) and even more effective (75% survival)
when treatment was started earlier, i.e., given
on days 4, 5, 6, 7 and 8 (curve 3). Adminis-
tration of DEF (curves 4 and 5) increased
mortality when compared to saline-treated
controls. These data demonstrate the protec-
tive effect of SOD against influenza virus
mortality in CBA mice.
Allopurinol at doses of 5 to 50 mg/kg per
day did not show any effect on mouse sur-
vival rate, which did not differ from control
mice (data not shown). This lack of effect of
allopurinol confirms the suggestion that the
main source of free radicals during influ-
enza-caused lung edema seems to be due to
activated neutrophils (9) which appear in
large numbers in the bronchoalveolar fluid
and lungs of infected mice and not to the
xanthine-xanthine oxidase system as pro-
posed by others (4). It has been shown that
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Figure 1 - Effect of antioxidant treatment on the mortality of mice infected with influenza
virus. Male CBA mice were infected intranasally with 2-5 LD50 lung influenza virus A/Aichi/
2/68 (H2N2). Data are reported as the mean of 3 independent experiments for which 20
mice were used for each group. Curve 1: Control group. Curve 2: SOD, 1000 U/day iv on
days 5, 6, 7 and 8 after inoculation. Curve 3: SOD, 1000 U/day iv on days 4, 5, 6, 7 and 8 after
inoculation. Curve 4: Desferrioxamine, 25 mg/kg per day sc, divided into two applications.
Curve 5: Desferrioxamine, 100 mg/kg per day sc, divided into two applications.1335
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SOD can prevent O2
· · · · ·--dependent formation
of a neutrophil chemotactic factor (10).
We suggest that in the present experi-
ments SOD was effective mainly due to its
ability to inhibit neutrophil influx into the
lungs by decreasing the concentration of the
chemotactic factor and therefore by rupture
of the “feedback loop” during the inflamma-
tion process.
The results obtained with DEF were un-
expected. Doses of 10, 25 and 50 mg/kg per
day potentiated the effect of the virus and
increased mortality (Figure 1, curve 4) and
more than 100 mg/kg led to the rapid death
of all the mice, i.e., 5-7 days after inocula-
tion (Figure 1, curve 5). DEF at the dose of 5
mg/kg per day had no effect on the survival
of infected mice. Since the LD50 for mice is
250 mg/kg per day (11), the death of mice
inoculated with doses of 25 to 100 mg/kg per
day was not due to the toxicity of DEF.
Indeed, doses of 50, 100 and 150 mg/kg per
day had no effect on healthy mice. It has
been shown that DEF can stimulate the acute
inflammatory induction phase of chronic al-
lergic monoarthritis at low doses (12), pre-
sumably due to its prooxidant effect under
certain conditions. Indeed in our experiments
both low (10 mg/kg per day) and high (150
mg/kg per day) doses of DEF aggravated the
condition of mice infected with influenza
virus. The prooxidant properties of DEF have
been reported by others (13-16).  In vitro
studies have shown that in the presence of O2
and Fe(II), DEF is a prooxidant (17). In our
experimental model the pathological pro-
cess occurs in the lungs which have a high
level of oxygen compared to other tissues.
When this process is accompanied by eryth-
rocyte lysis and hemoglobin release with an
increase in Fe(II) concentration, conditions
similar to those reported by Yegorov (17)
probably occur, and therefore DEF acts as a
prooxidant leading to aggravation of the
pathological process and, in the case of in-
fection with the influenza virus, to increased
mortality.
The present results suggest that SOD can
protect against the hemorrhagic lung edema
caused by influenza virus and furthermore
indicate that caution is necessary when DEF
is administered during the acute inflamma-
tory process accompanied by erythrocyte ly-
sis. The lack of effect of allopurinol indi-
cates that the xanthine-xanthine oxidase sys-
tem does not play a major role in the hemor-
rhagic lung edema of mice infected with
influenza virus.
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